Healthcare / Medical DevicesTel Aviv
$255.10
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-222000.00 · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
84.8%
↑Gross Margin
-1416.3%
↓Debt/Equity
-1.99
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-79.0%
FCF CAGR
—
FCF margin
-39.8%
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $98000.0 · net income $-6.8M · FCF $-39000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $98000.00 | $98000.00 | $181000.00 | $282000.00 | $10.6M |
| Net Income | $-6.8M | $-6.8M | $-8.3M | $-25.3M | $-25.0M |
| EBITDA | $-6.7M | $-6.7M | $-6.6M | $-17.5M | $-26.4M |
| EPS | — | — | -3.22 | -9.97 | -9.87 |
| Gross Margin | -1416.3% | -1416.3% | -769.6% | -659.2% | 61.3% |
| Operating Margin | -6888.8% | -6888.8% | -3481.2% | -5535.8% | -233.3% |
| Net Margin | -6919.4% | -6919.4% | -4574.0% | -8969.1% | -235.1% |
| Balance Sheet | |||||
| Debt/Equity | -1.99 | -1.99 | -6.42 | 3.92 | 1.36 |
| Current Ratio | 0.54 | 0.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-39000.00 | $-39000.00 | $-222000.00 | $-2.2M | $-4.7M |
| Returns | |||||
| ROE | 84.8% | 84.8% | 332.0% | -583.7% | -86.8% |
| Valuation | |||||
| P/B | — | — | — | 320.68 | 62.31 |
| Growth & Yield | |||||
| Revenue Growth | -45.9% | -45.9% | -35.8% | -97.4% | — |
| EPS Growth | — | — | 67.7% | -1.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.22 → n/d
Residual
+17.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.